 MaxCyte Inc AIM:MXCT has raised guidance after a strong start to the year that saw the cell engineering specialists revenues increase by 78 in the first quarter. It expects the top-line growth of at least 25 from the core business, while milestone income from licensing agreements is set to be in the order of US4mln. 